Mielóma multiplex: vizsgálatok itt: Izrael
35 trials · From ClinicalTrials.gov, checked 2026. november 10.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- Where
- Haifa, Jerusalem, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 410 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT05730036 · EU 2022-501396-62-00 - 1. fázisTaking peopleA Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Where
- Haifa, Jerusalem, Ramat Gan
- Életkor
- 18 év and over
- People
- 317 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT05137054 · EU 2023-506247-42-00 - 1. fázisTaking peopleA Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
- Where
- Haifa, Jerusalem, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Genentech, Inc.
See details and how to joinNCT05927571 · EU 2023-504657-13-00 - 2. fázisTaking peopleStudy of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
- Where
- Jerusalem
- Életkor
- 18 év and over
- People
- 180
- Run by
- Polina Stepensky
See details and how to joinNCT06971380 - 2. fázisTaking peopleA Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Haifa, Jerusalem, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 510 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04634552 · EU 2023-504581-29-00 - 4. fázisTaking peopleA Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Where
- Tel Aviv
- Életkor
- 18 év and over
- People
- 295 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05201781 · EU 2023-505530-10-00 - 3. fázisTaking peopleA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Where
- Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 1590 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00 - 3. fázisTaking peopleA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Beersheba, Haifa, Jerusalem, Ramat Gan, Ramat Poriya, Tel Aviv
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07258511 · EU 2025-522007-18-00 - 3. fázisTaking peopleA Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
- Where
- Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07665450 - 3. fázisTaking peopleA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Where
- Haifa, Jerusalem, Kfar Saba, Peatch Tikva, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 810 worldwide
- Run by
- Celgene
See details and how to joinNCT05519085 - 2. fázisTaking peopleA Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
- Where
- Afula, Ashdod, Ashkelon, Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 127 worldwide
- Run by
- Karyopharm Therapeutics Inc
See details and how to joinNCT04414475 · EU 2024-511608-18-00 - 3. fázisTaking peopleA Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Where
- Jerusalem, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 440 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00 - 3. fázisTaking peopleA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Where
- Beersheba, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 1060 worldwide
- Run by
- Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00 - 1/2. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Where
- Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06953960 · EU 2024-517140-65-00 - 1. fázisTaking peopleA Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Haifa, Tel Aviv
- Életkor
- 18 év and over
- People
- 186 worldwide
- Run by
- Genentech, Inc.
See details and how to joinNCT04910568 · EU 2023-507019-36-00 - 1. fázisTaking peopleA Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- Where
- Jerusalem, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 127 worldwide
- Run by
- AbbVie
See details and how to joinNCT07409246 - 1. fázisNot yet taking people in IzraelPhase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis
- Where
- Jerusalem
- Életkor
- 18 év and over
- People
- 160
- Run by
- Hadassah Medical Organization
See details and how to joinNCT07874334 - 1/2. fázisTaking peopleA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- Where
- Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan
- Életkor
- 18 év to 64 év
- People
- 602 worldwide
- Run by
- AbbVie
See details and how to joinNCT06892522 · EU 2024-515770-27-00 - 1. fázisTaking peopleStudy of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
- Where
- Jerusalem
- Életkor
- 18 év and over
- People
- 60
- Run by
- Hadassah Medical Organization
See details and how to joinNCT07333430 - No phaseTaking peopleEarly Detection and Screening of Hematological Malignancies - SANGUINE
- Where
- Tel Aviv
- Életkor
- 18 év and over
- People
- 3000 worldwide
- Run by
- JaxBio Ltd
See details and how to joinNCT05735704 - 1/2. fázisTaking peopleIsatuximab in Combination With Novel Agents in RRMM - Master Protocol
- Where
- Jerusalem, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 258 worldwide
- Run by
- Sanofi
See details and how to joinNCT04643002 - 3. fázisTaking peopleA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Where
- Jerusalem
- Életkor
- 18 év and over
- People
- 183 worldwide
- Run by
- Takeda
See details and how to joinNCT06980480 · EU 2024-518420-80-00 - 3. fázisTaking peopleCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Where
- Haifa, Jerusalem, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 380 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07555938 · EU 2025-524028-23-00 - 3. fázisTaking peoplePhase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Where
- Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 1594 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT05243797 · EU 2023-510384-36-00 - No phaseTaking peopleIntegrative Therapies in Multiple Myeloma
- Where
- Haifa
- Életkor
- 18 év and over
- People
- 300
- Run by
- Bnai Zion Medical Center
See details and how to joinNCT06515249